# to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

> **NCT07265466** · PHASE1 · RECRUITING · sponsor: **Onconic Therapeutics Inc.** · enrollment: 96 (estimated)

## Conditions studied

- Drug Drug Interaction (DDI)

## Interventions

- **DRUG:** JP-1366 and clopidogrel
- **DRUG:** JP-1366 and aspirin
- **DRUG:** JP-1366 and atorvastatin
- **DRUG:** JP-1366 and apixaban

## Key facts

- **NCT ID:** NCT07265466
- **Lead sponsor:** Onconic Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07265466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07265466, "to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07265466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*